Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial* [PDF]
Thomas Danne +7 more
openalex +1 more source
The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. [PDF]
Thalange N +6 more
europepmc +1 more source
Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance [PDF]
David Owens
core +1 more source
Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years. [PDF]
Thalange N +4 more
europepmc +1 more source
Impact of structure and formulation changes on the function of insulin products. [PDF]
Yang Y +4 more
europepmc +1 more source
Insulin detemir: A new option for the treatment of diabetes [PDF]
Martha M. Funnell
openalex +1 more source

